Compounds of 2-sulphanilamido-5-carboxythiazole with vasoconstrictors and their solutions



peutic activity m n Nov. 20, 1945 Philip S. Winnek and Ina, ware COMPOUNDS OF Z-SO'LP- S- XY'IHIAZ VASOCON- ABBO OLIL WITH STRICTORS AND THEIR SOLUTIONS Earllhnockstahlenlndlanapolil, Ind assigno Kansas City,*Mo.,

I! to Alllcd- Laboratories,

a corporation or Dola- No Drawing. Application August 2, 1943.

Serial No. 497,044

13 Claims.

tions. The spectacular results obtained when these drugs were administered internally prompted many clinicians to apply them locally, thus producing a greater concentration at the site of infection. Favorable results reported in the healing of infected wounds, compound fractures, and many other conditions, have led to the attempted use of these drugs for the local treatment or the nose and paranasal sinuses.

Saturated solutions of sulphanilamide for the treatment of sinusitis have been tried with some success, but the low solubility and weak chemotherapeutic activity of this compound against many common pathogenic organisms leaves much to be desired.

Solutions of greater strength and chemotherahave been made available by the introduction of sodium salts of sulphathiazole, sulphadiazine and sulphapyridine, which are readily soluble in distilled water. However, these drugs are highly alkaline and have been found to cause extensive damage to the nasal and other mucosa.

In most cases the use of a vasoconstrictor in conjunction with sulphanilamide derivatives would appear to oflfer advantages for the relief of nasal congestionand assure the accessibility of the entire nasal cavity to the solution.

The present invention discloses a class of salts and solutions prepared from said salts which have properties that make them particularly advantageous for the treatment of infections of the nose and paranasal sinuses, and other mucosa infections. Thes salts have the desired chemotherapeutic effects and. are soluble under conditions which do not produce the dam n action. to the membrane and mucosaltissue, as do the alkaline sulphenamide compounds previously mentioned.

2-sulphanilamido-5-carboxythiazole is a fairly acidic compound that possesses a chemotherapeutic activity or the same order in magnitude as sulphathiazole. It readily forms salts with the common mucosa shrinkin agents which are readily soluble in aqueous solutions and normally possessing a pH oi greater than 4. These solutions are stable and possess chemotherapeutic activity and the desirable mucosa shrinking property, They are also much less toxic than any previous preparation It is desirable to have 2-sulphanilamido-5- carboxythiazole in higher concentrations (2% to 20%), than thoseordinarily used tor the vasoconstrictor or shrinkinc asent (0.05% to 3%).

form of an alkali metal salt.

It will therefore be necessary to have an excess of the sulphonamide present over that required to form the salts with the vasoconstrictor.

The excess oi 2-sulphanilamido-5-tarboxythiazole may be neutralized and made readily water soluble by additions or an alkali metal hydroxide (sodium hydroxide). The solution will then contain the alkali metal salt of 2-sulphanilamido-B-carboxythiazole in concentrations up to 20% and the salts of 2-sulphanilamido-5- carboxythiazole and the vasoconstrictor in concentrations from 0.05% to 8%.

For example, ephedrine is frequently employed as a nasal ucosa shrinking agent as a 3% solution of its ydrochloride tain 2.46% of ephedrine. Approximately 8% solution of the salts of 2-sul-phani1amido-5-carboxythiazole and ephedrine is required to give 2.46% concentration of ephedrine-in the solution.

However, lesser concentrations of ephedrine are also used clinically asior example 1%. A solution containing 3% of the salts of 2-sulphanilamido-5-carboxythiazole and ephedrine will furnish the 1% concentration. It a 5% Z-sulphanilamido-5-carboxythiazole concentration is desired it will therefore be necessary to have an additional 3% of this substance present in. the The addition of alkali may be so regulated as to bring the solution to a selected pH. for example from l to 8.5.

It may also be of advantage to add to the solution small amounts of'preserving agents such as phenol, sodium sulphite, and the like, and/ or substances having synergistic action with the sulphonamide, such as urea, N,N-dichloroazodicarbonamidine and substances having a synergistic action with the mucosa shrinking agent, such as menthol and eucalyptoL Example 1 salts of ephedrine and 2-sulphanilamido-5- carboxythiazole OchoncmNnonaniNosoiNnci (5H; -UH

S-C-OOOH which solution will con- The product first turns tohasa' water using 2,389,582 Example 2 thiazole and 7.7 parts of 2-amino-heptane were dissolved in 300 parts of boiling distilled water. ggg mgg g ggg benzene, Upon cooling, the salts of Z-aminoheptane and v 2-sulphanilamido-5-carboxythiazole crystallized i Q from the solution. The crystals were separated C c11o11c1mrr|cmmNOsmNHO from the mother liquor by suction filtration, H washed with a small amount 01 water and dried.

5 parts or a-hvdroxy-p-aminopropyl benzene and parts oi 2-sulphanilamido-5-carboxythiazole are weighed out and added. A considerable part 01' the solids dissolve the amount of precipimixture is h'eated to boiling and sumcient hot water is added to cause complete solution. The hot solution is filtered and on cooling the white crystalline salts or a-hydroxy-p-aminopropylbenzene and 2-sulphanilamido-5-carboxythiazole separates out. It may be further purified by crystallization from hot activated charcoal to remove impurities. Ai'ter purification the product melts with decomposition at 165-166 C.

Emmplel Salts of desoxyephedrine and 2-sulph'anilamido-5-carboxythiazole S-GCOOH oominmrcnmmcsomnog 5 parts or 2-sulphanilam1do-5-carboxythiazole and 2.5 parts or desoxyephedrine are mixed and 30 parts of water are added. The reaction mixture becomes quite warm and all or vaccum desiccator over sulphuric acid and the salt 01' desoxyephedrine and2-su1phanilamido-5- carboxythiazole is obtained as a viscous tar which on scratching with a glass rod turns to a white crystalline solid. The product is very ygroscopic and is readily soluble in water and its aqueous solution has a weakly acidic reaction.

Example 4 Salts oi' ,B-aminopropylbenzene and 2-sulphanilamido-S-carboxythiazole Gomencmrnn SOINHC NH: \N; H

Fifteen parts of 2-sulphanilamido-5-carboxythiazole and two parts of sodium hydroxide were s-o-coon mixed with 100 parts of distilled water. The resuiting solution was mixed with a solution of 9.2

Example 5 Salts of 2-aminoheptane and z-sulph'anilamido-5-carboxythiazole s-c-coon n-cm c mcmmn NH: N- 11 Twenty parts of 2-sulphanilamido-5-carboxy- BOsNHC 30 parts of water are the solid material dissolves. The solution is evaporated in a and further drying They melted at 134-5 C. Recrystallization water did not alter the melting point.

Example 6 from - amino-3-hydroxy ethylbenzene were dissolved in pH with the formation of of l-a-hydroxy-p-methylamino-3-hydroxy ethyl- 20 parts of warm absolute alcohol. The solution was cooled. then diluted with about three times its volume of anhydrous ether, which caused separation of asticky, viscous oil. The oil was rubbed with a glass rod, decanting the supernatant liquid and. replacing it with anhydrous ether several "times; and gradually changed to a white powder. This powder, the desired salts, is very hygroscopic and freely soluble in water.

Example 7 Solution of salts oi l-e-hydroxy-p-methylamino-3-hydroxy ethylbenzene and- 2-sulphanilamido-5-carboxythiazole @caoncmuncm.

- s-c-ooon HzNQSOaNH-C.

While it is possible to prepare and isolate the salts oi. 2-sulphanilamido-s-carboxythiazole with all the common mucosa shrinking agents, it is sometimes more convenient to-prepare the aqueone solution for use without isolating the active salts. The following example illustrates such a preparation.

To parts of 0.25 per cent aqueous solution of l a hydroxy p methylaminoli hydroxy ethylbenzene hydrochloride are added 5 parts 01 2-sulphanilamide-5-carboxythiazole. The mixture is stirred and 10% aqueous sodium hydroxide is added gradually until'the resulting solution has a pH of 6 to 7. The 2-sulphanilamido- 5-carboxythiazole is 'completely dissolved at this a solution of the salts benzene and 2-sulphanilamido-5-carboxythiazole, ,and the sodium salt of 2-sulphanilamido-5-carboxythiazole.

Example 8 HOQOHIZHNHL 15 parts or z-sulphanilamido-5-car oxythialole Example 9 Solution of salts of 2-(1-naphthylmethyliimidazoline and 2-sulphanilamido-5-'carboxythiazole S-C-COOH parts of z-sulphanilamido-5-carboxythiazole were suspended in 100 parts of a 0.05% solution of 2-(1-naphthylmethyl) -imidazoline hydrochloride which contained in addition-0.742% potassium biphosphate, 0.223% potassium chloride, 0.258%sodium phosphate, 0.077% sodium chloride, 0.014% propyl p-hydroxybenzoate and 0.026% methyl p-hydroxybenzoate. .Ten per cent aqueous sodium hydroxide solution was then added slowly with stirring. The suspended solid gradually dissolved, and a clea solution of pH about 6.2, was obtained after addition of about 6.4 parts of th alkali solution. The solution was adjusted to pH 6.5 by further addition of sodium hydroxide' solution, about 0.4 parts additional being required.

The foregoing examples are merely-illustrative of suitable methods for preparing representative salts of the class and are not intended to limit the scope of the invention. Salts of 2-sulphanilamido-5-carboxythiazole can be prepared by the methods described with any of the other common vasoconstrictors as shown in the preceding examples as well as alpha-hydroxy-p-methylamino-i-hydroxy ethylbenzene, p-methylamino- 4-hydroxypropylbenzene.

Our'experiments show as indicated by the preceding examples that certain of the salts are freely soluble in water while others are of limited solubility. These characteristics make some adaptable for use in aqueous solutions while the i others are better used in a, solid state.

Having thus described our invention, we claim: 1. An aqueous solution containing a 2-sulphanilamido-5-carboxythiazole salt of a basic vasoconstrictor and an alkali metal salt of 2-sulph- 5 anilamido-S-carboxythiazole.

.2. An aqueous solution containing a 2-sulphanilamido-fi-carboxythiazole sale of a basic vasoconstrictor and an alkali metal salt of 2-sulphanilamido-S-carboxythiazole, said salt being present in concentrations of 0.05% to 8% and the alkali metal salt of 2-sulphanilamido-5-carboxythiazole in concentrations up to 3. An aqueous solution containing a 2-sulphanilamido-5-carboxythiazole salt of a basic vasom constrictor and an alkali metal salt of 2-sulphanilamido-S-carbomthiazole, said salt being present in concentrations of 0.05% to 8% and the alkali metal salt of 2-sulphanilamido-5-carboxy- .thiazole in concentrations up to 20%, the solution 2 having a. pH value greater than 4 and less than 4. An aqueous solution containing a Z-sulphanilamido-5-carboxythiazole salt of a basic vasoconstrictor and an alkali metal salt of 2-sulpha- '2 nilamido-5-carboxythiazole and a preserving agent, said salt being present in concentrations of 0.05% to 8% and the alkali metal salt of 2-sulphanilamido-B-carboxythiazola in concentrations up to 20%. I

80 5. A 2-sulphanilamido-5-carboxythiazole salt of a basic vasoconstrictor.

6. An aqueous solution of a 2-sulphanllamido- 5-carboxythiazole salt-oi a basic vasoconstrictor, said solution having a pH value greater than 4 and less than 8.5.

7. A 2-sulphanilamidd-5-carboxythiazole salt of a vasoconstrictor having a salt-forming amine group.

8. A 2-sulphanilamido-5-carboxythiazole salt 41 of a phenylallwlamine having vasoconstrictor action.

-9. A 2-sulphanilamido-5-carboxyth.iazole salt of an alkylamine having vasoconstrictor action.

10. A 2-sulphanilamido-5-carboxythiazole salt 45 of an imidazoline having vasoconstrictor action.

11. The 2-sulphanilamido 5 carboxythiazole salt of alpha-hydroxy-beta-methylamino-3-hydroxyethylbenzene.

12. The 2-sulphanilamido-5 -carboxythiazole salt of para-hydroxy-alpha-methyl-beta-phenylethylamine.

13. The 2 sulphanilamido-5-carboxythiazole salt of desoxyephedrine.

. PHILIP S. WINNEK.

EARL R. BOCKS'IAHLER. 

